
Cerevast Therapeutics provides non-invasive SonoLysis therapy for vascular disorders using proprietary technology.
Cerevast Therapeutics, founded in September 2009, is a medical technology company focused on developing non-invasive SonoLysis therapies for treating acute ischemic stroke and other vascular disorders. Their flagship product, the ClotBust-ERTM, is an ultrasonic headframe designed to be easily deployed by emergency room staff to administer ultrasound energy for SonoLysis therapy. The company aims to revolutionize emergency stroke treatment with its operator-independent device, ensuring rapid and safe intervention.
Notable figures associated with Cerevast include its experienced management team and board of directors, who bring extensive expertise in medical technology and healthcare innovation. The company has garnered attention from prominent investors in the medical field, supporting its research and development efforts. Key achievements include advancing their pipeline programs in retinal vein occlusion and transcranial ultrasound therapies. Cerevast's impact lies in its potential to significantly improve outcomes for stroke patients through innovative, non-invasive treatment solutions.

CereVasc
cerevasc.com

Cervel Neurotech
cervel.com

SonoVascular
sonovascular.com

NeuroVasx

Cognition Medical

Cerebrotech Medical Systems

NeuRx Medical
neurxmed.com

Waveclear

Nervive

Neurosonics Medical

StrokeDx
stroke-dx.com

Rist Neurovascular
ristneuro.com

Imperative Care

Rapidpulse
rapidpulsemed.com

Boston Neurosciences
Companies similar to Cerevast Therapeutics include CereVasc, Cervel Neurotech, SonoVascular and NeuroVasx.
Cerevast Therapeutics was founded in 2009.
Cerevast Therapeutics' headquarters is located in Redmond, WA, US.
Cerevast Therapeutics' most recent funding round was for $11.4M (USD) in March 2015.
As of Mar 6, 2015, Cerevast Therapeutics has raised a total of $24.4M (USD).
Cerevast Therapeutics has 30 employees as of Feb 5, 2024.